Table 2.

Detailed description of the 22 patients who experienced elevations in alanine and aspartate aminotransferases and clinical failure event(s), if any, during the AMBITION trial.

Patient ID	Randomized treatment	Treatment at time of first elevation in ALT/AST	Days after IP initiation first ALT/AST elevation observed	Description of clinical failure event(s), if applicable
313	Combination	Combination	59	Not applicable
1563	Combination	Combination	225	Not applicable
191	Combination	Combination	699	Not applicable
192	Combination	Combination	288	Death
242	Combination	Combination	83	Hospitalization, disease progression, unsatisfactory long-term clinical response
872	Combination	Combination	60	Disease progression
1158	Combination	Combination	699	Not applicable
1073	Combination	Combination	372	Not applicable
588	Combination	None: Combination IP stopped on day 9	29	Death
771	Combination	Combination	412	Not applicable
794	Combination	Combination	15	Hospitalization, death
1107	Ambrisentan	Ambrisentan	106	Not applicable
621	Ambrisentan	Ambrisentan	814	Disease progression, hospitalization, unsatisfactory long-term clinical response
631	Ambrisentan	Ambrisentan	141	Disease progression, hospitalization
385	Ambrisentan	Ambrisentan	507	Not applicable
144	Ambrisentan	Ambrisentan	562	Not applicable
1539	Ambrisentan	BCT	127 (AST elevation)	Hospitalization, death
			142 (AST and TBili elevation)
153	Ambrisentan	Ambrisentan	765	Death
41	Tadalafil	Tadalafil	142	Not applicable
1188	Tadalafil	Tadalafil	158	Not applicable
1181	Tadalafil	Tadalafil	143	Not applicable
583	Tadalafil	None: BCT IP stopped on day 874	901	Disease progression, hospitalization, death

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCT, blinded combination therapy; IP, investigational product; TBili, total bilirubin.